Oxytocin and vasopressin signaling in health and disease.

Neurohypophysial peptides are ancient and evolutionarily highly conserved neuropeptides that regulate many crucial physiological functions in vertebrates and invertebrates. The human neurohypophysial oxytocin/vasopressin (OT/VP) signaling system with its four receptors has become an attractive drug target for a variety of diseases, including cancer, pain, cardiovascular indications, and neurological disorders. Despite its promise, drug development faces hurdles, including signaling complexity, selectivity and off-target concerns, translational interspecies differences, and inefficient drug delivery. In this review we dive into the complexity of the OT/VP signaling system in health and disease, provide an overview of relevant pharmacological probes, and discuss the latest trends in therapeutic lead discovery and drug development.
Competing Interests: Declaration of interests M.M. holds a patent in the oxytocin space: Kremsmayr, T. and Muttenthaler, M. Highly stable oxytocin derivatives, EP21216288, PCT/EP2022/087248. The other authors have no interests declared.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)